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Chapter 1: Introduction to Gold Nanorods and Their Application to Optical 
Coherence Tomography 
 
Introduction 
In the field of ophthalmology, optical coherence tomography (OCT) is an imaging 
modality that is widely used in the clinical setting while also being a valuable tool for 
researchers
1
. OCT non-invasively provides fast, high-resolution information about the structure 
of the tissues it images. Clinically, this allows it to detect changes caused by age-related macular 
degeneration (AMD), diabetic retinopathy (DR), and glaucoma
2–4
. These diseases are among the 
most common causes of irreversible vision loss in the developed and developing world.  
Despite the obvious clinical utility of OCT, it can currently only detect a disease when it 
has progressed to the point of causing structural change to the tissue being imaged. This 
shortcoming is most acute in the retina because many diseases affecting that tissue can cause 
vision loss prior to, or concurrent with, changes in tissue structure that are visible on standard 
OCT
5,6
. The research presented in this dissertation will address this significant limitation by 
increasing the amount of information that can be generated by OCT systems when performing 
retinal imaging. More specifically, we want to move beyond simple structural assessments of 
retinal morphology into functional assessments of physiology or molecular expression. 
To achieve this goal we seek to enhance the native strengths of OCT systems by 
introducing contrast agents that respond to physiological or molecular changes in tissue by 
altering their concentration therein. If an OCT system can detect these changes in contrast agent 
concentration, it will gain the ability to report on physiological and structural changes in tissue 
simultaneously while maintaining its high spatial resolution. Creating contrast agents that are 
compatible with OCT systems is difficult because the systems use a coherent light source to 
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create images of tissue, and any contrast agent that destroys this coherence, such as a 
fluorophore, is largely invisible to OCT systems natively. 
So, to generate contrast using OCT systems, a contrast agent needs to absorb or reflect 
light in the spectral range emitted and detected by the system, while being able to reach the tissue 
being imaged
7
. We use gold nanorods (GNR) for this purpose. GNR are excellent candidates for 
OCT contrast-enhancement because their absorption and reflectivity are tunable in degree and 
wavelength, and they are amenable to versatile surface functionalization
8
. Additionally, since 
gold itself is generally considered biocompatible GNR are a viable candidate for clinical 
translation. In this dissertation we will present a number of studies involving the 
functionalization and delivery of GNR, as well as the retinal imaging of GNR using standard 
OCT systems.  
The retina presents a particularly difficult target for contrast-enhancement of OCT 
because it has a wide range of reflectivity in its different layers. This becomes a more significant 
issue in disease states, or animal models of disease states, that further create heterogeneous tissue 
reflectivity. This variable reflectivity is naturally at odds with the detection of a contrast agent 
that changes reflectivity and makes it difficult to detect GNR using standard OCT technology. 
We address this issue by combining OCT adjuncts and GNR technology. OCT adjuncts 
work in conjunction with OCT systems to enhance them in some way, usually by providing them 
with more information to assess or by altering how existing data is processed. These 
improvements can allow for the detection of contrast agents where previously it was impossible. 
Along those lines, we will also present a number of studies related to the imaging of GNR in vivo 
and in vitro using OCT adjunct imaging systems.  
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Background 
The studies we present are at the intersection of retinal physiology, optical coherence 
tomography, and gold nanorod biochemistry. For the remainder of this chapter, we will present 
background information that helps in understanding these technologies, with an emphasis on 
those that are relevant to our studies. 
 
Optical Coherence Tomography 
Optical coherence tomography is a non-invasive imaging modality developed in the early 
90s that offers micron-scale resolution images tissue structure at a speed that is unmatched by 
any other imaging modality
1
. Its principal drawback is its relatively poor depth of penetration. 
Given these characteristics, OCT has become a clinical gold standard for ocular imaging, since 
that organ allows for excellent light penetration. It is also a versatile research tool, with a number 
of emerging applications being studied including cancer imaging, lymph node imaging, and 
imaging of blood flow and immune response
9
. 
In terms of function, optical coherence tomography has been called “ultrasound with 
light” because it measures the degree to which light in the UV-vis spectrum bounces off of its 
target. While this is a fitting analogy, the reality of how OCT operates is considerably more 
complex, and some understanding is necessary to appreciate the challenge and opportunities 
associated with enhancing optical coherence tomography imaging using adjunct technologies or 
exogenous contrast agents.  
It is impossible using existing technologies to detect the distinct returning pulses of light 
emitted by retinal tissues that are spaced tens of microns apart. Given the speed of light, the 
returning signals would be separated in time by femtoseconds. As a result, OCT systems actually 
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detect standing interference patterns created by a light source interacting with itself, after being 
split into a beam going to the sample arm or a reference arm. This interference pattern allows 
OCT systems to determine the degree and depth of reflectivity in the imaging target. As a result, 
the basic measurement reported by optical coherence tomography systems is reflectivity versus 
depth
1
. It is important that the light source is minimally coherent as this determines the resolution 
of the resulting images. The coherence length of an OCT beam dictates over what physical 
distance the light is capable of interfering with itself. A shorter coherence length is the product of 
a broader spectrum (less coherent) light source
10
. The broader the spectrum of the light source, 
the shorter the coherence length, and the better the axial resolution of the resulting 
measurement
1
. This single measurement is known as an A-scan. By iterating this process across 
a tissue, multiple A-scans can be collated into a B-scan, and ultimately a three-dimensional 
representation of the imaged tissue can be formed by combining multiple B-scans. Recent 
advances in native optical coherence tomography imaging systems have focused on improving 
its already impressive spatial resolution in addition to other enhancements in overall image 
quality
11,12
.  
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Retinal Anatomy on OCT 
 
 
Figure 1: The Mouse Retina on OCT. Note that like all standard OCT images, the data is presented in 
grayscale. Legend: vitreous humor (VIT), inner limiting membrane (ILM), retinal ganglion cell layer (RGC), 
inner and outer plexiform and nuclear layers (IPL, INL, OPL, ONL), photoreceptor inner and outer 
segments (IS/OS), retinal pigemented epithelium (RPE), Bruch’s membrane (BR), and the choroid (Chor). 
 
As the studies presented here are largely concerned with retinal imaging using OCT, a 
brief aside regarding retinal anatomy as it appears on OCT is prudent. Figure 1 is example of the 
quality of retinal imaging available using a standard, commercial OCT system for rodent eyes. 
Light would be approaching this retina from the top of the screen, and the uppermost part of the 
retina on this image is the inner retina. The innermost retina is comprised of the inner limiting 
membrane (ILM) which is a barrier to movement from the vitreous into the retina. The retinal 
ganglion cell (RGC) layer, axons from which become the retinal nerve fiber layer that merges to 
become the optic nerve at the optic nerve head, is directly adjacent. Moving further back into the 
retina (down on the image) are the inner plexiform and nuclear layers (IPL, INL) and outer 
plexiform and outer nuclear layers (OPL, ONL). These layers are comprised of neurons that 
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communicate between RGCs and the outer layers of the retina, which contain rod and cone 
photoreceptors. The rods and cones are the base functional units of vision, responding to photons 
by undergoing rapid physiological and ultimately electrochemical changes that are 
communicated to the visual processing centers of the brain via the neuroretinal pathways just 
discussed. They have inner and outer segments (IS/OS) which are not clearly distinguished in 
Figure 1. Just behind the rods and cones is the retinal pigmented epithelium (RPE), which is very 
bright on OCT. Bruch’s membrane (BR), which is on the border of the retina and the choroid 
(Chor), is also present in that area. The choroid is an important blood supply to the outer retina. 
These layers of the outer retina and inner choroid are sometimes difficult to distinguish from one 
another, as is demonstrated by Figure 1. 
 
Contrast Agents in Optical Coherence Tomography 
While optical coherence tomography is a light-based imaging modality, the design of 
contrast agents that are compatible with it is complicated by the requirement that the minimal 
coherence of the light source be maintained during and after its interaction with the contrast 
agent. For this reason, fluorophores and other dyes standardly used to provide contrast with light-
based imaging modalities are not generally detected by optical coherence tomography systems
13
.  
There are a number of contrast agents that have been studied for use with optical 
coherence tomography and its adjuncts, primarily because of their ability to interact with the 
wavelengths of light emitted and detected by optical coherence tomography systems, or interact 
in some way with the adjunct systems. Notable examples of potential exogenous contrast agents 
include ferrous nanoparticles
14
, light-absorbing dyes (e.g. indocyanine green)
15
, polystyrene 
beads, or gold nanoparticles
16
. Of these, we think the most promising for contrast enhancement 
 
 
7 
 
of OCT is the gold nanoparticle, in particular GNR because its unique optical properties allow it 
to interact very strongly with the light emitted and detected by OCT systems. 
 
The Synthesis of GNR and Their Optical Properties  
The most common and facile method of GNR synthesis is called wet synthesis, and it 
involves seeding a mixture of colloidal gold and cetyltrimethylammonium bromide in order to 
begin the process of GNR growth
17
. By altering relative concentrations of reactants and reaction 
times a variety of GNR can be made with variable lengths and widths
18
. This length-to-width (or 
“aspect”) ratio of the GNR governs the wavelength with which it maximally interacts8. This 
wavelength is known as its surface plasmon resonance (SPR), which is an effect caused by 
collective oscillations of electrons on the GNR surface. At this SPR wavelength, the GNR both 
absorbs and reflects light strongly relative to its size, which is a valuable property for an OCT 
contrast agent. The degree to which the light is absorbed versus reflected is related to the overall 
size of the nanorod. The nature of a GNR’s interaction with light has had considerable 
experimental verification
19
. This means that the optical properties of GNR are quite tailorable 
depending on their desired application. Figure 2 depicts a standard GNR as seen using 
transmission electron microscopy (TEM).   
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Figure 2: Representative TEM image of GNR. This figure shows bare GNR with a typical shape. 
 
Gold Nanorod Detoxification, Delivery, and Targeting 
With these optical properties, GNR are an ideal contrast agent for OCT imaging 
modalities. The problem then becomes one of stabilization and delivery of the nanoparticles to a 
place where they can be successfully imaged. Wet synthesis of gold nanorods leaves a CTAB 
coating on the particle. The stability of the GNR in solution is dependent on its CTAB 
concentration. Unfortunately the necessary concentration of CTAB is cytotoxic, immunogenic, 
and potentially disruptive to OCT imaging applications
20
. 
This means that there is the need for a coating that prevents nanoparticle aggregation and 
is not cytotoxic. A number of coatings have been studied with suitable properties, and they can 
be broadly grouped into two categories
21
. First, electrostatic coatings rely on creating and 
maintaining a surface charge on the gold nanoparticle that is of sufficient strength to repulse 
similarly charged nearby nanoparticles
22
. While CTAB itself would technically fall into this 
category, these coatings can be applied and maintained in such a way that they are not reliant on 
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solute concentration for their stability in solution, or following injection. The major drawback of 
this class of coatings is that while their charge is self-repulsive, it can attract oppositely charged 
molecules in vivo.  
The second class of stabilizing coatings is the steric inhibitors, which broadly rely on 
their bulk rather than charge to prevent aggregation of nanoparticles
23
. As these are usually 
covalently bonded to the gold surface, they retain their aggregation-preventing properties both in 
solution and following injection
24
. While their lack of surface charge can reduce the interaction 
of these nanoparticles with other biological components, their large size can potentially make 
delivery more difficult
25
. Polyethylene glycol, which features heavily in the GNR constructs used 
in our studies, is a member of this group
26
.  
 
Optical Coherence Tomography Adjuncts 
As previously mentioned, optical coherence tomography systems natively only provide 
reflectivity versus depth information, which can be a limitation in heterogeneous tissue. In an 
effort to address this deficiency and provide more informative OCT images, researchers have 
combined novel imaging technologies with OCT systems in what are known as OCT adjuncts
27
.  
One OCT adjunct system is photothermal OCT (PT-OCT)
28
. This technology uses an 
additional laser source to heat the tissue being imaged in a pulsed fashion. This heating alters the 
temperature of the surrounding media. This temperature change alters the refractive index of the 
surrounding media, which changes the optical path length of the light detected by OCT systems 
through that media. By detecting these periodic changes in optical path length it is possible to 
determine the degree to which a given tissue absorbs the light emitted by the photothermal light 
source. This technology offers another dimension along which to distinguish between tissue 
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types or exogenous contrast agents. PT-OCT is compatible with GNR contrast agents because 
GNR can absorb light and emit it as heat, thereby generating a photothermal (PT) signal
16,29
. 
Another OCT adjunct is spectroscopic OCT, which includes split-spectrum and spectral-
fractionation optical coherence tomography (SF-OCT). These technologies probe the entire 
spectrum of light emitted and detected by an optical coherence tomography system in order to 
measure changes in tissue reflectivity across narrower bands of this spectrum
30
. This allows for 
the generation of data relating to the spectrum of light reflected by tissue or a contrast agent. A 
significant drawback of this technology is that there is an inherent trade-off between spectral and 
spatial resolution in the system. However, with native optical coherence tomography systems 
approaching sub-micron axial resolutions, this trade-off could be favorable under a number of 
circumstances. SF-OCT is compatible with GNR contrast agents because the spectrum across 
which GNR maximally reflects light can be offset relative to the SF-OCT system’s emission 
spectrum, creating the spectral contrast the system is designed to detect
30
. 
There are several additional adjunct optical coherence tomography systems used in 
research settings. Photoacoustic optical coherence tomography relies on the photoacoustic effect, 
the emission of sound waves by certain particles after they have absorbed energy at a certain 
wavelength, to pinpoint the location of relevant particles in the tissue being imaged
31,32
. Like 
photothermal optical coherence tomography, this approach requires an additional laser source to 
be integrated into the imaging system.  Unlike photothermal optical coherence tomography, it 
also requires an additional detector to pinpoint the emitting sound waves in the tissue
33
. Pump-
probe OCT detects dyes by acquiring an optical coherence tomography image, photobleaching 
the dyes with a second integrated light source, and reacquiring the image to detect changes due 
to the bleaching
15
. Magnetomotive OCT uses the manipulation of ferromagnetic particles by 
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external magnetic fields to alter the tissue in a way that can be detected by OCT  systems, 
although this requires some way to administer that field concurrent with the imaging, as well as 
ferromagnetic contrast agents
14,34
.  
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Chapter 2: Gold Nanorod Detoxification, Functionalization, and OCT 
Imaging 
 
Introduction 
Despite the desirability of gold nanorods as optical coherence tomography contrast 
agents, there are significant barriers to their effective use in in vivo ocular imaging. To be a 
viable candidate, the GNR construct must be stable both in solution and after injection. 
Instability in this case refers to the aggregation of GNR that occurs readily if the surface coating 
does not sterically or electrostatically inhibit it. This aggregation alters the optical properties of 
the GNR, thus compromising their utility as contrast agents
35
.  
An early study using OCT to image intravitreally injected GNR showed the formation of 
opacities of unknown composition following intravitreal injection of bare GNR in conjunction 
with an immune response to the injections
36
. It was unclear what caused this anomaly on imaging 
studies, but one hypothesis is that the surface charge of the GNR interacted with proteins in the 
vitreous in a way that produced the opacity and may have played a role in the immune response. 
These charge-mediated interactions represent another barrier to using GNR to contrast-enhance 
OCT.  
Additionally, GNR must be able to reach the tissue in which they are being designed to 
create contrast, in this case the retina. Delivery of relatively large GNR (~10x35nm) to the retina 
requires considering surface functionalizations that enhance their ability to penetrate retinal 
tissue in addition to animal models that may allow GNR delivery while maintaining clinical 
relevance. 
The studies presented in this chapter represent our initial steps toward contrast-enhanced 
OCT. We establish that changes in GNR functionalization can improve the imaging potential of 
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GNR. We additionally probe how GNR might be delivered to the retina following intravitreal or 
intravenous injections. And we assess our ability to detect GNR in retinal tissue using OCT in 
vivo. And throughout this process, we strive to maintain the translational relevance of our studies 
as it relates to the contrast enhancement of OCT.   
 
Methods 
Gold Nanorod Surface Functionalization 
Several GNR constructs are used in the experiments outlined in this chapter. Bare GNR 
with peak SPR of 808nm and a diameter of 10nm were purchased from a commercial source 
(A12-10-808; Nanopartz; Loveland, CO, USA), and these are referred to as “bare” or “CTAB-
coated” GNR. This SPR peak is used for all GNR in the studies reported in this chapter because 
we theorized that this peak would maximally interact with the 800-900nm spectrum of the OCT 
system we use for imaging. These bare GNR were modified by sonication with polyethylene 
glycol-thiol constructs (Laysan Bio.; Arab, AL, USA) at a 10:1 molar overconcentration of 
PEG:CTAB for an hour to displace the CTAB with a PEG surface coating. In some cases the 
surface coating had an additional modified Tat peptide covalently bound to it. Tat is an HIV-
surface peptide that enhances cellular uptake. Its sequence is RKKRRORRR.  The products 
created following this displacement are called PEG-GNR or Tat-GNR, respectively.  
Displacement of CTAB was confirmed via surface-assisted laser desorption-ionization 
time-of-flight mass spectrometry (SALDI-TOF-MS) (Voyager Elite; PerSeptive Biosystems; 
Framingham, MA, USA). SALDI uses the GNR surface to capture laser energy and generate 
unique ionized fragments determined by the composition of the GNR and its surface 
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functionalization
37
. SALDI of the GNR proceeded following calibration of the mass 
spectrometer with red phosphorous. All readings were taken in positive ion mode.  
Figure 3a shows that SALDI of our bare GNR reports strong peak at 356 m/z caused by 
ionized gold-bromine particles, specifically of the form Au-Br2, indicating the expected covalent 
bond between the nanoparticle gold surface and the bromine in CTAB. This result provides an 
efficient way to determine if residual CTAB remains on the GNR constructs. Figure 3b shows 
that our PEG polymer totally displaces CTAB on our PEG-GNRs.  
 
Figure 3: SALDI-MS of GNR Constructs. This figure shows the results of SALDI mass spectrometry run on 
bare GNR and PEG-GNR. (A) shows a large peak at 356m/z (arrow). This peak is associated with Au-BR2, 
which is expected given the gold-bromine bond present on the surface of bare GNR. (B) demonstrates the loss 
of this peak (arrow) confirming displacement of surface CTAB in PEG-GNRs. (A,B) also demonstrate strong 
gold peaks near 197m/z (asterisks), which is expected when assaying GNR. 
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Additionally, GNR with a SPR of 808nm and a diameter of 10nm and a surface coating 
with a carboxyl moiety were purchased commercially (C12-10/750-TC-50; Nanopartz; 
Loveland, CO, USA). Surface functionalization of these GNR was achieved in a directed fashion 
using ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (Thermo Fisher Scientific; 
Waltham, MA, USA) crosslinking in the presence of N-hydroxysulfosuccinimide (sulfo-NHS) 
(Thermo Fisher Scientific, Waltham, MA, USA). The EDC coupling reaction allows the 
attachment of primary amine groups, such as those present on antibodies, to carboxyl moieties 
present on the surface of our GNR. The addition of sulfo-NHS to the reaction mixture improves 
the yield. We used two antibodies in this study. The first is a rat anti-ICAM2 antibody (Thermo 
Fisher Scientific, Waltham, MA, USA) which is our “targeted” antibody. ICAM2 is 
constitutively expressed on vascular endothelial cells. The second antibody is a rat IgG with no 
known reactivity to murine antigens (Thermo Fisher Scientific, Waltham, MA, USA) which is 
our control or “untargeted” antibody. The reaction proceeded via the addition of 1012 GNR to our 
reaction mixture followed by the addition of EDC and sulfo-NHS at 10-fold and 25-fold molar 
overconcentrations relative to surface carboxyl moieties in 1mL of deionized water. This mixture 
was allowed to react at room temperature for 2 hours with a magnetic stirring rod spinning at 60 
rpm continuously mixing the solution. The GNR were then purified via centrifugation at 18,000g 
for 45 minutes followed by resuspension in deionized water. Following resuspension, either the 
targeted or untargeted antibody was added to the reaction mixture at 50-fold molar 
overconcentration relative to surface carboxyl moieties present on the GNR. This solution was 
allowed to react for an additional 2 hours at room temperature with a magnetic stirring rod 
spinning at 60 rpm to facilitate mixing. Following this reaction, antibody-functionalized GNR 
were purified by three rounds of centrifugation at 18,000g for 45 minutes followed by final 
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resuspension in isotonic phosphate-buffered saline (PBS) prior to intravenous injection. These 
purified GNR are referred to as “targeted” and “untargeted” GNR respectively. Unreacted 
antibody was retained and purified to assess for reaction yield via BCA assay, which was 
approximately 20 percent. Additionally, transmission electron microscopy was used to ensure 
that GNR size and morphology was unchanged by these reactions. Table 1 summarizes the GNR 
constructs we use in the studies in this chapter. 
 
Name Dia-SPR Method Functional Group 
Bare GNR 10-808 As Purchased CTAB 
Peg-GNR 10-808 CTAB 
Displacement 
PEG 
Tat-GNR 10-808 CTAB 
Displacement 
modTat 
Untargeted GNR 10-808 EDC Crosslinking IgG 
Targeted GNR 10-808 EDC Crosslinking ICAM2 
Table 1: Summary of GNR Constructs Used in Experiments Reported in Chapter 2. This table lists the GNR 
constructs discussed in this chapter by their common name (Name), size and SPR peak in nm (Dia-SPR), 
method of surface functionalization (Method), and salient surface moiety (Functional Group). Note that 
CTAB displacement means surface CTAB was displaced by a thiol-linked PEG polymer.  
 
Intravitreal and Intravenous GNR Injections 
All animal treatments followed all requirements of the Vanderbilt University Institutional 
Animal Care and Use Committee and adhered to the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. 
Wild-type (C57BL/6) mice aged 8-10 weeks were used in all experiments reported in this 
chapter. For all procedures including imaging, animals were anesthetized via the intraperitoneal 
injection of a drug mixture containing 13.2mg/ml ketamine and 1.5mg/ml xylazine in sterile 
water, with a total injected volume equal to 3.7mL/kg of animal body weight. For ocular 
procedures, GenTeal lubricant eye gel (Alcon, Hunenberg, Switzerland) was applied to the 
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cornea to prevent ocular dryness. Intravenous (tail-vein) and intravitreal injections were used to 
deliver GNR or appropriate controls, depending on the nature of the experiment being 
conducted. For tail-vein injections, 100uL of a GNR solution or PBS was injected 8 hours prior 
to any imaging being performed. Intravitreal GNR injections were performed ~3 minutes prior to 
imaging. Heating pads assisted in post-procedure recovery. 
 
Laser-Induced Choroidal Neovascularization 
The laser-induced choroidal neovascularization (LCNV) model was implemented with 
laser photocoagulation by a laser system (Carl Zeiss Meditec; Jena, Germany) with a laser 
(Coherence; Santa Clara, CA, USA) operating at 532nm and 120W pulsed for 0.1 seconds. The 
eye was manually manipulated to permit visualization of the mouse fundus as well as focusing of 
the laser on the RPE layer prior to firing. A microscope cover slide coupled to the eye with a 
2.5% hydroxypropyl methylcellulose solution was used to aid in the operation. The spot size of 
the laser on the retina was 100 microns, and we attempted to place four lesions evenly spaced 
from one another, centered on the optic nerve head and approximately two optic disc diameters 
from it. We attempted to avoid damaging any major blood vessels with the laser, and any 
significant bleeding associated with the lasering process was noted and that lesion was excluded 
from further study. Lasering produces visible vapor bubbles following laser firing, which is a 
reliable indication that Bruch’s membrane has been ruptured, which is necessary for 
implementing the LCNV model. Representative day 5 lesions were imaged via bright-light 
fundoscopy using the Micron IV imaging system (Pheonix Research Labs; Pleasanton, CA, 
USA). 
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Ex Vivo Immunohistochemistry and Imaging 
Wild-type (C57BL/6) mice aged 8-10 weeks were treated in the LCNV model as 
previously described. Five days after lasering, the mice were intravenously injected with PBS, 
untargeted GNR, or targeted GNR. After allowing the GNR 8 hours to accumulate, the mice 
were anesthetized and enucleated. Their globes were fixed in 10% neutral buffered formalin 
(ThermoFisher Scientific; Waltham, MA, USA). The choroids were dissected from the 
surrounding tissue, washed with tris-buffered saline (TBS) (Corning Cell Gro; Corning; Corning, 
NY, USA), and blocked with 3% BSA in 0.1% Tween (Sigma-Aldrich; St. Louis, MO, USA) for 
2 hours at room temperature. They were then stained with anti-Rat IgG antibody conjugated to 
Alexa Fluor 594 (A11007; Invitrogen; Waltham, MA, USA) and mounted with Prolong Gold 
with DAPI mounting media (P36942; ThermoFisher Scientific; Waltham, MA, USA). Following 
this treatment the choroids were imaged using an Eclipse-Ti microscope (Nikon; Melville, NY, 
USA).  
 
In Vivo Optical Coherence Tomography 
For all imaging done in this chapter, we used a commercial OCT system with a mouse 
retinal imaging lens operating in the 800nm-900nm range (Bioptigen, Inc.; Morrisville, NC, 
USA). Imaging data was acquired using 1000 A-scans/ B-scan and up to 100 B-scans for our 
largest retinal scans.  
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Results 
Gold Nanorod Detoxification 
For our first experimental attempt to visualize GNR using OCT, we injected bare GNR 
intravitreally and immediately imaged the result. Theoretically, GNR injected into the vitreous 
humor should be visible as small bright spots against the dark background of the vitreous, 
consistent with their strong scattering properties.  However, previous studies published of similar 
injections shoed the formation of an amorphous opacity in the vitreous. As Figure 4 shows, we 
got a similar result following intravitreal injections of bare GNR. The opacity formed within 
minutes of injection and persisted for the duration of imaging, and obstructed the view of the 
retina. Figure 4 demonstrates the strong shadowing effect it has on the retina behind it. The 
image is also noteworthy for the lack of any punctate scattering effects we might expect from 
GNR. 
 
Figure 4: In Vivo Retinal Imaging Following Intravitreal Injection of Bare GNR. This image was acquired 
within minutes of bare GNR injection. It shows the formation of an amorphous opacity (arrow) throughout 
the vitreous. The opacity causes a considerable shadowing effect on the retina behind it (asterisk).  
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Given this strong and rapid interaction between the vitreous humor and the bare GNR, as 
well as the existing evidence for CTAB toxicity and stability issues, we opted to replace the 
CTAB with a steric inhibitor of aggregation, polyethylene glycol (PEG). PEG coating allows for 
GNR to maintain stability in solution, and should prevent the charge-mediated interaction 
between the GNR surface and surrounding proteins. Additionally, PEG is widely used to alter the 
properties of pharmaceutical compounds and is considered to be biocompatible
38
. 
 
 
Figure 5: In Vivo Retinal Imaging Following Intravitreal Injection of PEG-GNR. As above, this image was 
acquired within minutes of the intravitreal injection of PEG-GNR. This image was taken through the middle 
of the eye and therefore shows the optic nerve head (asterisk). The presence of discrete scatterers (arrows) in 
the tissue is apparent near the inner retina extending into the vitreous. Of note, the amorphous mass and 
shadowing effects associated with bare GNR injections are not present here.  
 
Figure 5 demonstrates that intravitreal injections of these PEG-GNR were successful in 
that they delivered GNR to the inner limiting membrane, plainly visible as punctate scatterers 
against the darkness of the vitreous humor. The size of these scatterers is larger than might be 
expected based on the size of GNR relative to the tissue being imaged, which might indicate 
some aggregation has occurred. The retina is plainly visible behind the PEG-GNR with no 
significant shadowing effects. This result is a step forward in terms of achieving surface 
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functionalization of GNR that is compatible with OCT imaging. However, as Figure 5 also 
shows, we could find no evidence that the PEG-GNR moved through the ILM into the retina, 
thus limiting their utility as retinal contrast agents. We attempted one more set of intravitreal 
injections with Tat-GNR, under the theory that the modTat surface peptide might promote 
intracellular uptake of the GNR through the ILM, but the results of the experiment with Tat-
GNR were indistinguishable from those with PEG-GNR. 
 
In Vivo Intravenous Gold Nanorod Delivery 
In light of these mixed results with intravitreal injections, we decided to test the efficacy 
of intravenous GNR delivery to the retina via tail-vein injection. This change in delivery method 
presented several new challenges. The blood-retina barrier is generally not permeable to large 
molecular weight nanoparticles, which would make it difficult to get our GNR into the retinal 
tissue
39,40
. Also, it was unclear where these GNR might localize in the retina for our imaging 
purposes. If the GNR were widely dispersed, they might be difficult to detect on imaging. 
To address these concerns, we chose to image our GNR in the laser-induced choroidal 
neovascularization, or LCNV, model
41
. This mouse model is often used as an acute 
approximation of “wet” or neovascular AMD, which allows our studies to maintain their 
translational relevance.
42,43
 In LCNV, an ultraviolet-range laser is targeted to the RPE/Bruch’s 
membrane layer of the outer retina. The energy from the laser is absorbed by the RPE and 
released as heat which severely damages Bruch’s membrane. Where this laser injury occurs, 
endothelial cells and leaky vessels derived from the choroidal vasculature proliferate into the 
subretinal space, creating a lesion
44,45
. The morphology of this lesion changes over time. The 
lesion grows in size until the seventh day after the laser injury, when it plateaus and then begins 
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to spontaneously resolve
46
. This entire process can take several weeks. LCNV lesions are 
localized to the area surrounding the initial laser burn
47
.  
Due to the inflammatory milieu surrounding these lesions, there are a number of 
antibody-targetable surface ligands that are upregulated in in this animal model, the most 
important for our studies being CD102/ICAM2
48,49
. This biomarker is constitutively expressed 
on endothelial cells, and almost all LCNV lesions contain increased numbers of endothelial 
cells
50
. Using this model in our studies has many potential benefits. It weakens the blood-retinal 
barrier to allow the accumulation of large nanoparticles in a way that still maintains the 
translational relevance of the studies. It also provides a visible, localized area where GNR would 
be expected to accumulate both passively and due to potential targeting effects.  
Figure 6 shows a fundoscopy image taken five days after treatment in the LCNV model. 
The lesions are plainly visible and localized to the area surrounding the laser burn. Some blood is 
also visible in the upper left quadrant, which is a possible side effect of lasering. In our 
experiments in the LCNV model, we wanted to assess the ability of GNR to accumulate in the 
laser lesions, and in particular we wanted to assess the potential of GNR surface 
functionalization to generate a targeted effect in the LCNV model. Mice were treated in the 
LCNV model, and on day 5 post-lasering, they were tail-vein injected with PBS, untargeted, or 
targeted GNR. We gave the GNR 8 hours to accumulate in the lesions, and then isolated the 
choroids. The choroids were stained with a DAPI nuclear stain and an Alexa Fluor 594-
conjugatee anti-rat-IgG antibody prior to flat mounting. The only potential sources of rat IgG in 
these mouse choroids were the antibodies covalently bound to the surface of the injected GNR. 
Essentially, we used our intravenously injected GNR as primary antibody for an 
immunohistochemical study in order to assess GNR delivery.   
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Figure 6: In Vivo Bright-Light Fundoscopy of Mouse Retina Treated in LCNV Model. This is a 
representative image of a mouse retina treated in the LCNV model take five days after lasering. The optic 
nerve head (asterisk) is visible and surrounded by blood vessels radiating away from it. The four laser 
injuries (arrows) are evenly spaced about the optic nerve head. Note the presence of red blood on the left half 
of the image.  
 
Figure 7a-c shows that all of the lesions stain with DAPI nuclear stain. Since all LCNV lesions 
involve the proliferation of cells, the DAPI results are as expected. Figure 7f shows that the 
strongest anti-rat IgG staining occurs in the mouse injected with targeted GNR. There is still 
some anti-rat-IgG staining in the lesion of the mouse injected with untargeted GNR (7e), and 
there is virtually none in the lesion of the PBS-injected mouse (7d). While this is not a 
quantitative study, it does demonstrate that there is a qualitative increase in GNR accumulation 
in LCNV lesions following the injection of untargeted GNR and particularly targeted GNR. This 
piece of data alone is not proof of retinal GNR delivery or a targeting effect. However, it did 
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inform our decision to pursue in vivo retinal imaging of intravenously injected GNR using OCT 
using the LCNV model. 
 
 
Figure 7: Ex Vivo Flatmounts of Stained Mouse Choroids Treated in the LCNV Model Following GNR 
Injection. Each paired column represents a single LCNV lesion treated with a DAPI nuclear stain (A,B,C) 
and an anti-rat IgG antibody conjugated to an AlexaFluor 495 fluorophore (D,E,F). (A,D) show a 
representative lesion from a mouse injected with PBS. (B,E) show a lesion of a mouse injected with 
untargeted GNR. (C,F) show a lesion of  a mouse injected with targeted GNR. All three lesions show DAPI 
staining, but the strongest anti-rat-IgG counterstaining is present in the lesion from the mouse injected with 
targeted GNR.  
 
In Vivo OCT Imaging of Intravenously Delivered GNR 
After the successful ex vivo result, we sought to assess whether these GNR constructs 
would be visible on standard OCT imaging in vivo. We initiated a pilot study that followed the 
same design as the previous ex vivo study, with mice injected on day-5 post-lasering with PBS 
(n=10 eyes) or targeted GNR (n=10 eyes) and imaged at 8, 24, and 48 hour post-injection time 
points. Laser lesions were imaged and assessed for the presence of visible scatterers or detectible 
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large-scale changes in light reflection and absorption that would be consistent with GNR 
accumulation. 
 
 
Figure 8: In Vivo OCT Imaging of the Retina of a Mouse Treated in the LCNV Model Following Intravenous 
PBS Injection. This is a representative image of a day-5 LCNV lesion in the mouse retina imaged 8 hours 
after intravenous PBS injection. It demonstrates a large morphological change extending from the choroid 
into the retinal space (arrows) with endogenous punctate scatterers present as well (asterisks). 
 
Figure 8 shows a typical day 5 LCNV lesion imaged natively by an OCT system, 8 hours 
after PBS injection. There are a number of changes in the degree of reflectivity across the tissue 
due presumably to the agglomeration of cells and other biological detritus following laser injury. 
The image demonstrates that there is already a high degree of heterogeneous scattering occurring 
even without GNR injections, which will complicate GNR detection. In fact, the punctate 
scattering shown in Figure 6 is similar to that associated with GNR injection in Figure 4 
(intravitreal PEG-GNR injection), although there are no GNR present in Figure 6.  
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Figure 9: In Vivo OCT Imaging of the Retina of a Mouse Treated in the LCNV Model Following Intravenous 
Targeted GNR Injection. This is a representative image of an LCNV lesion in the mouse retina acquired by 
OCT five days after lasering and 8 hours after the intravenous injection of targeted GNR. As in Figure 6, 
there is a characteristic morphological change in the outer retina (arrows). But this image is most noteworthy 
for the lack of any detectable changes due to the GNR injections. 
 
Figure 9 shows a day-5 lesion on OCT imaged 8 hours after the injection of targeted 
GNR. There is no discernible difference in the degree of tissue reflectivity either in totality or in 
texture associated with GNR injection. There were also no changes in overall absorption that we 
were able to measure. While many of the in vivo images presented in this chapter were taken as 
part of larger studies, the imaging results were not quantified e.g. in terms of lesion brightness. 
This quantification was not performed because it was unclear from the images what changes 
might have occurred due to GNR accumulation or where they might be localized. In short, since 
we could not see any changes to quantify, quantitative analysis was not indicated. These results 
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suggest that the scattering caused by GNR becomes very difficult to detect in the 
heterogeneously scattering environment of the retina, particularly in an LCNV lesion.  
 
Discussion 
On a positive note, the studies reported in this chapter show us developing tools that got 
us closer to our goal of contrast-enhanced OCT, but we also report the setback of being unable to 
successfully image GNR in the retina in vivo. We demonstrate that we could effectively and 
totally displace the CTAB present on the surface of “bare” gold nanorods with PEG, and that this 
significantly improved the properties of the GNR as an imaging adjuvant. The impressive benefit 
of novel surface functionalizations, particularly those involving PEG, to the performance of 
GNR became clear with these studies. Further, we developed chemical approaches to modify 
surface PEG by covalently attaching various uptake- and target- altering proteins.  
We demonstrate that we can inject GNR intravitreally and intravenously, and that we can 
image retinal tissue following these injections in vivo. This is a major step forward in OCT 
imaging of GNR, because there was concern that the visually obstructive reaction to bare GNR 
in the vitreous previously published would preclude the use of GNR as a source of contrast in 
retinal studies
36
.  
This effect of bare GNR on the vitreous is interesting in its own right. Previous work 
showing a similar visual effect also provides evidence that these GNR are immunogenic, so it 
was assumed that the immune system was responsible for the optical effect
36
. However, the 
speed of this effect suggests that it might not be mediated entirely by the immune system per se, 
although CTAB is toxic to cells and it has a clear role. We were able to assess the speed of this 
effect because we could image our animals within minutes of the intravitreal injections, while the 
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previous study waited ten times longer between injection and imaging, at minimum. Given its 
immediacy, this opacity could be the result of a charge-mediated interaction between the GNR 
surface and the proteins present in the vitreous, although it could also be due to GNR 
internalization by immune cells, or some combination of these and other effects. Clarifying the 
exact nature of this effect would require further study. 
We additionally determined that LCNV was a viable animal model for studying and 
imaging GNR delivery. Our immunohistochemical staining of flat mounted choroids, while 
imperfect, suggested that GNR were being delivered to LCNV lesions in the retina, and that a 
targeting effect due to surface antibody selection was present as well. However, it became 
apparent that while we may be able to deliver GNR to LCNV lesions, we could not readily detect 
them using OCT due to the background noise caused by the heterogeneous retinal and choroidal 
tissue present in the laser lesions. This obstacle suggested that in order to achieve retinal imaging 
of GNR and thus contrast-enhanced OCT, we would need to rely on OCT imaging adjuncts 
capable of detecting targeted gold nanorods despite this background noise.   
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Chapter 3: In Vivo Imaging of GNR Using Photothermal Optical Coherence 
Tomography 
 
Introduction  
In the previous chapter we demonstrate that it is possible to construct and modify GNR to 
make them more amenable to imaging using OCT. However, we also show that standard OCT 
systems have great difficulty imaging GNR in the heterogeneously scattering tissue of the retina, 
which is one of our major goals. In this chapter, we address this deficiency by using 
photothermal OCT (PT-OCT) in combination with GNR for in vivo retinal imaging. 
As discussed in the background section of chapter 1, PT-OCT operates by using a laser 
source separate from the one used to generate the OCT image to heat whatever absorbers are 
present in the tissue being imaged
28
. These absorbers can be endogenous, as in the case of 
melanin in the RPE, or exogenous, as in the case of intravenously injected GNR
16
. The degree of 
heating in the tissue is variable, but is in the range of 1-3 degrees Celcius
51
. This degree of 
temperature increase is unlikely to cause any damage to ocular tissues, and no gross 
morphological changes due to PT-OCT heating were observed during our studies. Heating these 
absorbers ultimately changes the optical path length (OPL) of light passing through the 
surrounding media, which can be detected in the data collected by standard OCT systems
51
. The 
PT signal is reported as the magnitude of the change in optical path length in nanometers.  
Once again, GNR are a useful adjuvant for an OCT imaging adjunct, in this case because 
they are excellent light absorbers and their absorption peaks can be tuned to sit at the wavelength 
emitted by the PT source light
21
. This is an important aspect of the studies discussed in this 
chapter, as here we use GNR with absorption peaks tuned to the photothermal laser source at 
750nm rather than tuned to the OCT light source as in the previous chapter’s studies. The use of 
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GNR with PT-OCT has been previously demonstrated, although it has never before been 
demonstrated in the eye or more specifically for our research, the retina.  
To generate an appropriate target for our imaging studies in the mouse retina in vivo, we 
will again use the LCNV model in the mouse. As described in the previous chapter, this mouse 
model is often used as an acute approximation of “wet” or neovascular AMD42. It has the 
advantage of presenting a localized target for our photothermal imaging in addition to having 
abnormal vasculature that might serve to concentrate GNR in the lesions.  
In this chapter, we demonstrate the ability of PT-OCT technology to achieve in vivo 
retinal imaging of both endogenous (RPE melanin) and exogenous (GNR) contrast agents in the 
LCNV model. Additionally, we demonstrate the utility of PT-OCT detection of molecularly 
targeted GNR to generate high-resolution contrast-enhanced images physiological changes in the 
retina. To accomplish these goals, we first image wild-type and albino mice show that melanin is 
an endogenous PT-OCT contrast agent present in the mouse retina. Then we use PT-OCT to 
image mice treated in the LCNV model after intravenously injecting them with ICAM2-targeted 
GNR to assess our ability to detect these GNR in vivo over the melanin background signal. We 
use injections of untargeted GNR or PBS as controls for these experiments. In comparing the 
lesion-associated photothermal signal from these cohorts we can assess our ability to detect 
targeted exogenous contrast agents in the mouse retina using PT-OCT.  
The other question we consider in this chapter is whether PT-OCT imaging of GNR 
allows for the detection of clinically relevant physiological changes in the mouse retina in vivo. 
To model a clinically relevant change, we use the standard LCNV model as before, but in one 
eye of each mouse we inject anti-VEGF antibody, while in the other eye we inject PBS. VEGF 
signaling is a major driver of neovascularization in LCNV lesions, so we anticipate anti-VEGF 
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treatment to reduce the proliferation of neovascular endothelial cells in the lesions, thereby 
reducing lesion volume as well as the concentration of ICAM2-targeted GNR that will 
accumulate in these lesions
52–55
. Additionally, anti-VEGF treatments are a very common clinical 
therapeutic intervention in patients with wet AMD (which we model with LCNV), maintaining 
the translational relevance of this experiment. In assessing our ability to detect anti-VEGF-
induced changes to LCNV lesions in vivo, we are assessing the utility of PT-OCT imaging of 
GNR to detect clinically relevant physiological changes in the retina, which is one of our major 
goals with this research. The imaging of endogenous retinal melanin, the imaging of molecularly 
targeted GNR, and the detection of non-structural changes in LCNV lesions in vivo are all novel 
applications of PT-OCT technology. 
The work discussed in this chapter was performed as a collaborative effort. The studies 
discussed in this chapter have already been published either in Lapierre-Landry et al. (Sci. Rep., 
2017) or Gordon et al. (Trans. Vis. Sci. Tech., In Press)
16,56
. The figures and captions (modified 
in some cases) in this chapter are reprinted with permission from those authors.  
 
Methods 
Gold Nanorod Functionalization 
The GNR used in the studies reported in this chapter have dimensions of 10nm by 35nm, 
with peak absorption at 750nm. Aside from this change, GNR functionalization proceeded as 
described in chapter 2. We used the same two antibodies in this study as in the previous chapter. 
The first is a rat anti-ICAM2 antibody (Thermo Fisher Scientific, Waltham, MA, USA) which is 
our “targeted” antibody. The second antibody is a rat IgG with no known reactivity to murine 
antigens (Thermo Fisher Scientific, Waltham, MA, USA) which is our control or “untargeted” 
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antibody. The resulting GNR constructs are referred to as untargeted GNR and targeted GNR 
respectively.  
 
Animal Treatments, Drug and Contrast Agent Delivery, Lasering, and Imaging 
All animal treatments followed all requirements of the Vanderbilt University Institutional 
Animal Care and Use Committee and adhered to the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research. 
Male albino (BALB/c) and wild-type (C57BL/6) mice aged 8-10 weeks were used in all 
experiments reported in this chapter. For all imaging procedures, animals were anesthetized 
using continuous isoflurane administration (2-5%) in air either in a box or via nose cone. For 
procedures involving laser photocoagulation or injections (tail-vein or intravitreal), animals were 
anesthetized via the intraperitoneal injection of a drug mixture containing 13.2mg/ml ketamine 
and 1.5mg/ml xylazine in sterile water, with a total injected volume equal to 3.7mL/kg of animal 
body weight. For procedures involving the eye, GenTeal lubricant eye gel (Alcon, Hunenberg, 
Switzerland) was applied to the cornea to prevent ocular dryness. Regardless of the type of 
anesthesia or procedure performed, mice recovered on heating blankets until they were awake 
and behaving normally. 
All other injections were either intravenous or intravitreal. Intravenous tail-vein 
injections were used to deliver GNR or appropriate controls, while intravitreal injections were 
used to deliver anti-VEGF treatments or appropriate controls. For the tail-vein injections, 100uL 
of a GNR solution or PBS was injected 8 hours prior to any imaging being performed. 
Intravitreal injections were accomplished by the insertion of a small-guage needle through the 
mouse cornea behind the lens followed by the injection of either 2uL of anti-VEGF antibody 
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solution (AF-493-NA; R&D Systems; Minneapolis, MN, USA) in one eye of a mouse, with a 
PBS injection into the contralateral eye serving as an intravitreal injection control. Intravitreal 
injections were performed immediately following lasering. 
The laser-induced choroidal neovascularization (LCNV) model was implemented with 
laser photocoagulation by a laser system (Carl Zeiss Meditec; Jena, Germany) with a laser 
(Coherence; Santa Clara, CA, USA) operating at 532nm and 120W pulsed for 0.1 seconds, using 
the same procedure outlined in chapter 2. Representative day 5 lesions were imaged via bright-
light fundoscopy using the Micron IV imaging system (Pheonix Research Labs; Pleasanton, CA, 
USA) and via optical coherence tomography using our modified spectral-domain OCT system 
(Leica Microsystems Inc.; Buffalo Grove, IL, USA). 
For mice treated in the LCNV model, all imaging was done 5 days following laser 
photocoagulation, a time point chosen because it allows for the presence of vascular endothelial 
cells in the lesion without as significant a presence of RPE cells, which produce endogenous 
photothermal contrast that we sought to minimize
47
. This is demonstrated in Figure 10. Figure 
10b shows that the LCNV lesion itself has very few RPE cells in it on day 5 post-lasering, while 
Figure 10a demonstrates how this finding appears on OCT. For our albino vs wild-type PT-OCT 
studies, 6 eyes were imaged from 3 mice in each cohort. For our three-arm study of imaging 
GNR delivered to LCNV lesions, the PBS control arm had 21 eyes imaged, while the two GNR 
injected arms (targeted and untargeted GNR) had 14 eyes each. The study assessing the effects of 
anti-VEGF treatment on PT-OCT imaging of targeted GNR in lesions used 14 eyes from 7 mice 
for a paired analysis.  
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Figure 10: Comparison of Day 5 LCNV Lesions using OCT. (a,b) show representative OCT in vivo and H&E 
ex vivo images of day 5 LCNV lesions. The RPE (white and black arrowheads, respectively) is visibly 
disrupted. 
 
Instrumentation, Signal Analysis, and Image Correction 
For all imaging done in this chapter, we use a spectral domain OCT system (Leica 
Microsystems Inc.; Buffalo Grove, IL, USA) that was modified for PT-OCT imaging. The OCT 
system’s broadband light source was centered at 860nm (40nm bandwith), and the photothermal 
laser was centered at 750nm. The photothermal (PT) laser had a power of 8mW for all 
experiments discussed here and was amplitude modulated via an acousto-optic modulator 
(Brimrose; Sparks, MD, USA) at f0=500Hz (50% duty-cycle, square wave). The modified 
system repeated 700 A-scans (M-scans) in a given location to help derive a photothermal signal, 
and repeated this process 400 times to construct a B-scan (400 A-scans/B-scan). The data 
collected by the system was used to generate the photothermal signal, expressed as the change in 
optical path length in nanometers in the tissue due to heating caused by the photothermal laser 
source. Images were corrected for breathing artifacts common in live-animal retinal imaging 
using an algorithm from Guizar-Sicairos et al
57
. A thorough explanation of the data processing 
 
 
35 
 
required to isolate a photothermal signal from raw OCT interferogram data is available in 
Lapierre-Landry et al. (Sci. Rep., 2017)
16
. 
After deriving the photothermal signal from the raw data, the images were analyzed by 
hand-selecting the region of interest (ROI) corresponding to the extent of the LCNV lesion 
visible on a given B-scan. These selections were made to include the LCNV lesion while 
excluding the RPE layer, as this layer contains melanin that produces a strong photothermal 
signal. This selection was made while blinded to the photothermal signal associated with the 
lesion, which was our primary experimental endpoint. After making these selections for every B-
scan associated with a given lesion, those measurements were combined to create the overall 
lesion volume. These volumes were then used to calculate both a lesion size and total 
photothermal signal, from which average photothermal signal density can be derived by dividing 
photothermal signal by lesion volume. Exclusion criteria for a lesion from these studies included 
severely abnormal morphology, notably retinal detachment. Additionally, individual B-scans 
from a lesion volume were excluded if poor image quality prevented photothermal measurements 
to be taken, most commonly due to corneal opacities or the presence of gross blood in or near the 
retina.  
Further imaging was performed using the modified OCT system but without using the 
additional photothermal laser source. These images were used to estimate the size of LCNV 
lesions by measuring the lesion size on the B-scan with the maximal extent of the measured area 
of the associated LCNV lesion. This single B-scan lesion measurement is called a lesion 
diameter.    
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Significance Tests 
For the experiment comparing pigmented to albino mice, the differences between the two 
groups were assessed using the Mann-Whitney U test, which was used because the low number 
of samples necessitated a non-parametric statistical test. For the three-armed 
control/untargeted/targeted GNR experiment, a cluster analysis was performed in consultation 
with the Vanderbilt Biostatistics Department to determine the statistical significance of 
differences in the means the cohorts. A Tukey analysis was performed following estimations of 
statistical fixed effects between the three cohorts using a linear mixed effect model. This more 
complex statistical analysis was necessary because one or two eyes from a given mouse could 
have been used as part of the experimental cohort, and a for a given mouse both eyes were 
subject to the same tail-vein injection, meaning they cannot be treated as independent for 
experimental purposes. The final set of experiments involving paired anti-VEGF/PBS injections 
into different eyes of the same mouse was analyzed for statistical significance using a one-tailed 
Wilcoxon signed-rank analysis assessing differences in lesion-associated photothermal signal 
density, as well as in lesion size. This test was appropriate because of the paired nature of the 
experiments. In all cases a p-value ≤ 0.05 was considered significant. 
 
Results 
In Vivo Retinal Imaging of Albino and Wild-Type Mice Using PT-OCT 
Melanin is a known absorber of light across a broad spectrum, including the wavelength 
used by our photothermal laser source. In order to determine the extent to which melanin-
associated PT signals were detectable using in vivo imaging, the retinas of untreated BALB/c 
albino mice (n=6 eyes) and C57BL/6 mice (n=6 eyes) were imaged using our PT-OCT system. 
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The results are reported as a photothermal signal density across the entire image, rather than that 
associated with a lesion. 
 
 
Figure 11: In Vivo PT-OCT Imaging of Albino and Wild-Type Mouse Retinas. (A) Average retinal PTOCT 
signal for albino and wild-type mice, with error bars representing standard deviation. There is a significant 
increase in PT-OCT signal in the wild-type mice, with almost no signal present in the albino mice; **p≤0.01. 
(B,C) show representative images from wild-type and albino mice, respectively, with a green PT-OCT 
overlay. Legend: RPE (retinal pigmented epithelium), CO (choroid). This figure is reprinted here with 
permission of the authors from Lapierre-Landry et al. (Sci. Rep., 2017).  
 
Figure 11a shows there is virtually no detectable photothermal signal in any of the images 
of the retinas of albino mice, while there is considerable photothermal signal present in all of the 
retinas of wild-type mice. This is a statistically significant difference. Representative B-scans of 
retinas including a green photothermal signal overlay from the two cohorts are shown in Figure 
11b,c.  
 
In Vivo Retinal Imaging of GNR in the LCNV Model Using PT-OCT 
Following our successful detection of endogenous photothermal contrast in the mouse 
retina, we assess our ability to detect and evaluate exogenous contrast agents in vivo. C57BL/6 
mice were treated in the LCNV model. On day 5 post-lasering, the mice were tail-vein injected 
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with PBS, untargeted GNR, or targeted GNR. The targeted GNR were functionalized with anti-
ICAM2 antibody. 8 hours following the tail-vein injections, laser lesions from mice in each 
experimental group were selected and imaged and the lesions’ photothermal signal density was 
calculated. For the untargeted GNR cohort, photothermal signal density above baseline was used 
to assess the degree of passive accumulation of GNR in laser lesions. In the targeted cohort, the 
measurements assessed GNR accumulation for a targeting effect.   
 
 
Figure 12: PTOCT of Untargeted and Targeted GNR In Vivo. (a) Average PTOCT signal density for each 
cohort, with error bars representing standard error of the mean. There is a significant increase in this signal 
associated with both untargeted and targeted GNR injections versus PBS control. *p≤0.05; **p≤0.001.  (b-d) 
representative OCT B-scans of mice injected with PBS (b; n=21 eyes), untargeted GNR (c; n=14 eyes), and 
targeted GNR (d; n=14 eyes) respectively, with lesion-associated photothermal signal overlaid in gold. Note 
the increased concentration of photothermal signal associated with passive accumulation of GNR in the 
lesions, and the greater increase associated with the injection of targeted GNR. 
 
The results from the three cohorts are reported in Figure 12a as photothermal signal 
density in laser lesions for each of the three experimental cohorts. In mice injected with PBS, 
there was an average photothermal density of 2.82 nm/pixel (+/- 1.20 nm/pixel standard 
deviation, n=21 eyes), which is our minimum possible photothermal density measurement due to 
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melanin-induced background photothermal signal. The photothermal signal density in the 
untargeted GNR cohort (4.20 +/- 1.74 nm/pixel, n=14) is 1.49 times higher than in the PBS 
cohort, a statistically significant difference. The signal density in the targeted GNR cohort (4.89 
+/- 1.60 nm/pixel, n=14) was stronger still, at 1.73 times higher than background noise. While 
the difference between the targeted GNR and PBS cohorts is statistically significant, the 
difference between the targeted GNR and untargeted GNR cohorts is not, although there is a 
trend toward more signal from the targeted GNR. Representative B-scans of laser lesions with 
associated photothermal signal overlaid in gold from the three cohorts are shown in panels 12(b-
d). 
 
PT-OCT Imaging of Targeted GNR Accumulation After Anti-VEGF Injection in the 
LCNV Model 
One of the major goals of this research is to create tools that allow us to expand the 
purview of OCT beyond its current realm of structural imaging to allow the imaging of 
physiological changes in vivo. To accomplish this goal using PT-OCT and GNR technology, we 
treated wild-type mice in the LCNV model. Immediately following lasering, the mice were given 
an anti-VEGF treatment or a PBS control via intravitreal injection. The anti-VEGF compound 
was an anti-mouse-VEGF neutralizing antibody, and its presence in the retina should down-
regulate VEGF signaling and thus the extent of choroidal neovascularization and ICAM2 
expression in laser lesions
50,52
. On day 5 post-lasering (and post-intravitreal injection), mice were 
tail-vein injected with targeted GNR, as in the previous experiment. PT-OCT imaging of lesions 
was performed 8 hours after the tail-vein injections, and photothermal signal density of lesions 
from the anti-VEGF-injected and PBS-injected eyes were measured and compared.  
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We confirmed the efficacy of the anti-VEGF injections by demonstrating their ability to 
reduce the size of laser lesions as predicted. Lesion diameters for both the anti-VEGF and PBS 
cohorts (n=7 paired eyes in each cohort) are reported in Figure 13a, which shows that in every 
mouse, the anti-VEGF injected eye had a smaller lesion than the PBS-injected eye, which is a 
statistically significant difference. This result confirms that the anti-VEGF injections were 
having their intended physiological effects in this set of experiments, which would include 
decreased lesion volume, endothelial cell concentration, and vascular leakiness. Figure 13b-c 
shows representative OCT B-scans from each cohort. 
 
 
Figure 13: Estimates of Lesion Size With or Without Intravitreal Anti-VEGF Injection In Vivo. (a) shows the 
lesion diameter from every eye in both experimental cohorts, paired by mouse (n=7 mice). The results are 
ordered from greatest to least magnitude of difference. The statistical significance of the difference between 
the PBS and anti-VEGF eyes is assessed using a Wilcoxon signed-rank test. W=28; p ≤ 0.05. The OCT B-
scans in (b,c) show representative lesions from mice intravitreally injected with PBS and anti-VEGF 
respectively. Both images are from mouse 5. 
 
The same lesions were then assessed for PT signal density. As reported in Figure 14, eyes 
given the anti-VEGF intervention showed a measurable reduction in photothermal signal density 
associated with laser lesions. Again, since each mouse had one eye treated with anti-VEGF and 
one eye treated with PBS, a paired analysis could be performed. In 6 of 7 eyes, the anti-VEGF 
treatment reduced lesion-associated photothermal signal density, as reported in Figure 14a.  This 
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difference is statistically significant, and it indicates that physiological changes to the laser lesion 
microenvironment induced by anti-VEGF injections can be detected in vivo using PT-OCT and 
GNR technologies. Figure 14b-c shows representative laser lesions with photothermal signal 
overlaid. Both lesions are from the same mouse.  
 
 
Figure 14: PTOCT of Targeted GNR With or Without Intravitreal Anti-VEGF In Vivo. (a) PT signal density 
from every eye in both experimental cohorts, paired by mouse (n=7 mice). The results are ordered from 
greatest to least magnitude of difference with the horizontal axis numbers matching the eyes to those in 
Figure 13(a). The statistical significance of the difference between the PBS and anti-VEGF eyes was assessed 
using a Wilcoxon signed-rank test. W=27; p ≤ 0.05. (b,c) Representative images of OCT b-scans with overlaid 
lesion-associated photothermal signal, both from mouse 5. (b) shows a lesion from the eye given the anti-
VEGF injection, while (c) is from the PBS-injected control eye of the same mouse, which shows both a larger 
lesion and increased PT signal per pixel. 
 
Discussion 
OCT is the clinical gold standard in retinal imaging because it provides quick, easy, and 
highly detailed structural information about its target. However, it is limited due to its inability to 
generate physiological information about the tissues it images, since this information can provide 
valuable information about disease states or responses to therapy. Our goal with this research 
was to improve OCT by adding to it the ability to detect endogenous and exogenous contrast 
agents in vivo in the retina, and thereby improve the ability of OCT to image physiological 
processes. 
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 Regarding endogenous contrast agents, we show that RPE-associated melanin can be 
readily imaged in the mouse retina. We also demonstrate that there are no non-melanin sources 
of endogenous contrast in the retina. This is the first time retinal melanin has been directly 
imaged using OCT adjuncts, which is important because it could allow for rapid assessment of 
the health of the RPE layer in research and clinical settings. Some diseases have altered RPE and 
melanin distribution in the retina, notably AMD, and imaging of endogenous melanin using PT-
OCT could provide useful information about this disease in the future.   
Regarding exogenous contrast agents, we show that both targeted and untargeted GNR 
accumulation in laser lesions is detectable using PT-OCT. To demonstrate this, we used PT-OCT 
to image laser lesions in mice injected with PBS, untargeted GNR, or targeted GNR.  We were 
able to detect the accumulation of both targeted and untargeted GNR in laser lesions using PT-
OCT, but while there was a higher photothermal signal density in lesions from the targeted vs the 
untargeted group, this difference was not statistically significant. Part of the failure to achieve 
significance is likely due to the inherent variability of the LCNV model
58
.  
Additionally, these data suggest that a large proportion of the accumulation seen in the 
targeted GNR cohort is due to passive accumulation of GNR rather than active targeting due to 
surface antibodies. The exact mechanism by which fairly large GNR passively accumulate in 
LCNV lesions, or indeed in any tissue with abnormal vasculature, has yet to be elucidated. 
However, since we are using PT-OCT to detect the GNR, we know that they must be relatively 
immobile in the tissue being imaged to generate a photothermal signal that we can detect
59
. In 
the LCNV model specifically, it has been shown that rodent lesions are at their leakiest 4-7 day 
after lasering, and our imaging was performed in this window
58
. Additionally, it is understood 
that these lesions have abnormal hemodynamics leading to areas of very slow moving or even 
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static blood, which could increase GNR accumulation
60
. The vasculature itself is leaky, and 
although these GNR are on the edge in terms of size of what has been shown to extravasate in 
similar conditions, this is a possibility as well
61
.  
These effects are likely also related to our choice of an 8 hour post-injection imaging 
time point. Longer waiting periods could allow for increased clearance of unbound GNR from 
the lesions. A potentially useful theoretical model for the availability in tissue of immobilized 
GNR for PT-OCT imaging can be constructed by considering the rates of influx of GNR into 
tissue from the vascular circulation as well as clearance of GNR from tissue into the vasculature. 
The higher the GNR concentration in the damaged vasculature, the faster it should accumulate in 
tissue. Any force that prevents the egress of GNR from the tissue back into the vasculature will 
also increase the tissue concentration at a given time point. It is a reasonable hypothesis, then, 
that the targeting effect from antibodies on the GNR surface might be more apparent at time 
points past 24 hours, when the untargeted GNR have had time to be cleared from the tissue based 
on similar previous studies in tumor models
62
, while antibody binding might hold the targeted 
GNR in place. As previously stated, this is a theoretical model that might have relevance for 
future experimental design rather than anything derived from our current data. Indeed, it is 
difficult to assess to what degree the GNR being detected are truly immobilized in extravascular 
spaces versus being relatively immobile in abnormal lesion-associated vasculature, which 
complicates any theoretical understanding of GNR clearance rates.  
Finally, we assessed our ability to use exogenous contrast agents to detect physiological 
changes in the retina. Again using the LCNV model, we added intravitreal anti-VEGF treatment 
(or contralateral PBS controls) immediately following lasering to the experimental protocol, 
while also intravenously injecting targeted GNR on day 5 post-lasering. This allowed us to 
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perform a paired-eye analysis of the effects of anti-VEGF treatments on GNR accumulation. 
First, we report that as expected the treatment reduces LCNV lesion diameter to a statistically 
significant degree, which demonstrates the efficacy of the injections. Then, we assess the anti-
VEGF vs PBS cohorts for changes in photothermal signal density using PT-OCT. We found that 
there were statistically significant changes to signal density between these cohorts, likely due to 
changes in the extent of neovascular growth in the lesions. This differential GNR accumulation 
also likely represents changes in the functional ability of the existing or new vasculature in the 
lesions to prevent the extravasation of GNR into the surrounding tissue. In the future, this type of 
detection of physiological change using OCT imaging adjuncts could lead to improvements in 
health outcomes related to vision loss.  
There are a number of challenges associated with PT-OCT imaging of the retina in vivo, 
including the presence of endogenous contrast from melanin in the RPE layer. While, as 
discussed previously, this could have certain benefits to future applications of PT-OCT 
technology, it presents a difficulty in the detection of exogenous contrast agents like GNR. We 
use ROI selection to minimize this problem, but future improvements to both GNR size and 
targeting, to improve accumulation, and to PT-OCT technology, could offer solutions to this 
problem. We could tune the GNR and PT-OCT systems to operate in the NIR region, which 
should somewhat reduce the amount of photothermal signal generated by melanin. Additionally, 
we could alter our imaging time points and biomarker selection to optimize GNR accumulation. 
One interesting idea would be to evaluate photothermal signal at multiple wavelengths in tissue, 
which could improve our ability to distinguish exogenous from endogenous contrast. Despite 
these difficulties, in this study we were able to achieve our major goal of adding physiological 
information to OCT images.   
 
 
45 
 
Chapter 4: In Vitro Imaging of Intracellular GNR Using Spectral 
Fractionation Optical Coherence Tomography 
 
Introduction 
We demonstrated success in using PT-OCT to image GNR in vivo in the retina, but there 
were some limitations to the approach. So, we experimented with additional OCT adjuncts that 
might be useful for contrast enhancement of OCT. One such adjunct is spectral-fractionation 
OCT (SF-OCT)
30
. SF-OCT assesses the ratio between the amplitudes of shorter versus longer 
wavelengths returned as part of the native OCT signal from imaging targets. This technology 
allows for the detection of spectral changes in the backscatter from a tissue, endogenous or 
exogenous, that would be missed by a standard analysis of OCT data. There are considerable 
practical advantages to this approach. It detects strong spectrally and spatially localized 
scatterers that can be present at relatively low concentrations in tissue, where previous spectral 
OCT research relied on high concentrations of absorbing adjuvants, e.g. dyes
15,63,64
.  
Additionally, SF-OCT does not require additional light sources or detectors, but merely 
additional analysis of already existing OCT data which is an advantage over other OCT adjuncts 
discussed in chapter one, as well as representing an easier path to implementation than those that 
require, for example, dual-band OCT utilizing two distinct light sources
63
. In short, 
implementation of SF-OCT only requires a software upgrade, rather than a hardware one.  The 
only notable drawback to SF-OCT is that spectral resolution (the ability to detect less strong 
shifts in backscattered spectra) comes at the expense of spatial resolution. However, as OCT 
systems generally have spatial resolution to spare, we consider this a suitable tradeoff
65
.  
With their strong reflection of light at specific, tunable wavelengths due to their SPR, 
GNR are ideal candidates to generate contrast using SF-OCT
66
. With our goal being translational 
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applications of GNR that provide contrast enhancement to OCT, we decided to assess our ability 
to move GNR intracellularly and image them in that environment, which we hadn’t done 
previously. These studies are translationally relevant given the proliferation of cell-based 
therapies currently being advanced. First, we tested whether or not we could detect GNR in 
water or tissue phantoms using SF-OCT. Then, we tested our ability to use SF-OCT to image 
intracellularly localized GNR, also in tissue phantoms. The work discussed in this chapter is the 
result of a collaborative effort, and has been published in Jia et al. (Optics Express, 2015)
30
. 
Figures 16 and 17 are reprinted here with permission from the author.  
 
Methods 
OCT Imaging System and Image Analysis 
All imaging was conducted using a commercial FD-OCT system (RTVue-XR, Optovue, 
Fremond, CA) centered at 840 nm. The system was modified to allow the use of the raw spectral 
data it generated. This spectral data was separated into short and long wavelength halves with the 
split at 840nm. The halves were further split into four separate groups used to generate 
independent A-scans which were subsequently averaged for short- and long-wavelength spectral 
intensities. A ratio of these intensities known as a SLoW (short-long wavelength) ratio was 
generated and evaluated for every pixel above an intensity threshold of 3SD over the mean 
intensity of a scan. For a complete explanation of how the SLoW ratio is derived from raw OCT 
data, please see Jia et al. (Optics Express, 2015)
30
. Since the GNR being imaged by this system 
have an SPR at a longer wavelength than the middle of the OCT system spectrum, the “long” 
wavelengths of the short:long wavelength ratio will be increased. This is reported here as a 
negative SLoW ratio, in units of dB.  
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GNR Constructs 
The GNR used for the studies reported in this chapter had an SPR of 870nm after being 
diluted.  Aside from this difference, GNR functionalization was performed as described in 
chapter 2 to generate bare GNR and Tat-GNR. Quality assurance measures were performed as 
discussed in that chapter.  
 
GNR in Tissue Phantoms and RPE Cells 
For experiments involving GNR suspended in tissue phantoms, the phantoms were 
created via the serial dilution of intralipid 20% solution (Intralipid 20% emulsion, Sigma-
Aldrich, St. Louis, MO) down to 0.1%. GNR as previously described were diluted to 
concentrations of 5x10^10 GNR/mL using the already-diluted intralipid solution. The final 
phantom had a concentration of 5x10^10 GNR/mL in 0.1% intralipid. All imaging was done 
using 5mL tissue phantoms in 10mL test tubes. 
To localize GNR intracellularly, wells containing agar coated with 5x10^5 aRPE-19 cells 
were incubated with 10^9 Tat-GNR for 4 hours at 37 degrees celcius, followed by rinsing to 
remove excess GNR. Following treatment with trypsin, cells were concentrated via 
centrifugation and fixed using a 1% solution of neutral buffered formalin (NBF). Figure 15 is a 
TEM image that shows were successful in loading GNR into cells, and that the GNR were 
concentrated in cytoplasmic vesicles inside the cells. Cells were resuspended in 1% gelatin for 
subsequent imaging.  
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Figure 15: TEM of Intracellular Tat-GNR. This representative image demonstrates that the Tat-GNR move 
intracellularly following incubation with aRPE-19 cells, and in fact that they are in vesicles inside of those 
cells.  
 
Results 
SF-OCT Imaging of GNR in Tissue Phantom 
Initial SF-OCT imaging of GNR took place using standard CTAB-coated “bare” GNR 
suspended in tissue phantoms. Using SLoW ratio cutoffs of +/- 1dB to separate intralipid from 
GNR, three types of phantom were imaged and the results are reported in Figure 16. Figure 16a 
shows the intralipid solution, which has no detectable spectral shift. Figure 16b demonstrates that 
bare GNR suspended in water generate a considerable spectral shift, in this case color-coded red, 
and figure 16c demonstrates that GNR in intralipid still produces a detectable spectral shift 
despite the noisier background. These findings demonstrate that bare GNR can be detected using 
SF-OCT in water and in tissue phantoms.  
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Figure 16: SF-OCT Imaging of GNR in Water and Tissue Phantom. SF-OCT imaging of (a) 0.1% intralipid, 
(b) GNR in water, and (c) GNR in intralipid. The OCT image is in grayscale, with SF-OCT SLoW ratios 
colored in blue or red for +1 and -1 dB ratio measurements, respectively. The GNR are plainly visible in red 
in water and intralipid due to their increasing the long portion of the SLoW ratio. Reprinted with permission 
of authors from Jia et al. (Optics Express, 2015)
30
.  
 
SF-OCT Imaging of GNR in RPE Cells 
Consistent with our overarching goal of translational imaging of contrast agents using 
OCT, we next imaged RPE cells that had been incubated with Tat-GNR (labeled cells) in a tissue 
phantom. As controls, we used the phantom without any cells, as well as the phantom with cells 
that were not incubated with GNR (unlabeled cells). 
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Figure 17: SF-OCT Imaging of Intracellular GNR in Tissue Phantoms. SF-OCT images of (a) 1% gelatin, (b) 
aRPE-19 cells fixed and suspended in 1% gelatin, and (c) aRPE-19 cells previously incubated with Tat-GNR 
fixed and suspended in 1% gelatin. The SLoW ratio cutoffs here are moved to +/- 2dB. The characteristic 
SLoW ratio associated with GNR used in this study is still detectable in (c) even when the GNR are 
intracellularly localized. Reprinted with permission of authors from Jia et al. (Optics Express, 2015)
30
 
 
The SLoW ratio cutoffs used in this study were +/- 2 dB, based on the more variable 
signal from unlabeled RPE cells versus the background in the previous experiment. Figure 17 
shows that there was some positive (short-wavelength dominant) signal from the unlabeled RPE 
cells in the phantom (Figure 17b), and there was the expected considerable negative SLoW 
signal associated with labeled RPE cells suspended in a tissue phantom (Figure 17c). Of note, 
some of the labeled RPE cells had a positive SLoW signal, which could be due to characteristics 
of RPE cells, or due to aggregation of the GNR intracellularly following cell uptake. Some side-
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by-side aggregation would be consistent with these results and the findings shown in Figure 15. 
There was no detectible spectral signal from the phantom itself (Figure 17a). 
 
Discussion 
This brief chapter focuses on some of the exciting results obtained by SF-OCT imaging 
of GNR. The SPR of the GNR was chosen to be offset from the center of the OCT systems, in 
order to maximally impact the SLoW ratio. This is a different design principle than our initial 
studies which sought to align the center wavelength of the OCT system and the GNR SPR in 
order to generate maximal scattering and absorption from the GNR. 
We demonstrate that GNR can be detected using SF-OCT in a tissue phantom, which is a 
valuable proof of principle. Additionally, this detection comes while maintaining a clinically 
useful resolution (15nm) for the OCT system. More importantly, we demonstrate that we are able 
to detect intracellularly localized GNR in labeled cells suspended in a phantom. Given the 
negative results from the unlabeled cells, this result shows both that our GNR construct 
succeeded in entering cells in concentrations sufficient for detection, and that we could use GNR 
with SF-OCT for the generation of intracellular contrast in tissue phantoms. This is the first time 
this has been demonstrated, and it shows promise for future implementations of GNR and SF-
OCT technology. 
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Chapter 5: Summary and Conclusions 
 
The goal of translational imaging research is to improve the breadth, accuracy, and 
timeliness of information available for assessment prior to making clinically important decisions. 
For this reason, significant improvements in healthcare often are the result of innovations in 
imaging technologies. The goal of our research has been to improve optical coherence 
tomography in ways that could potentially be clinically translatable. OCT is already a mainstay 
of clinical ophthalmology because of its speed, resolution, and general ease of use. However, its 
major drawback is that it can generally only give us structural information about the tissue it is 
being used to image.  
The physical nature of OCT limits its native scope to structural information and also 
makes it difficult to design contrast agents that are compatible with it. Since OCT is 
fundamentally a form of interferometry, it cannot image fluorophores, for example, that might be 
used with other in vivo imaging modalities to provide contrast enhancement
13
. So, we needed a 
contrast agent with the potential to interact with OCT systems by absorbing or reflecting the light 
emitted and detected by the systems. Gold nanorods fit our contrast agent needs well, as they 
have versatile optical properties and gold is considered biocompatible. 
Our initial experiments simply involved the construction and testing of various GNR 
constructs for OCT imaging. The injection of bare (more accurately, CTAB-coated) GNR into 
the vitreous caused the rapid formation of an amorphous opacity that degraded imaging 
capabilities, which was consistent with results that were published at the same time as we were 
performing these experiments. That publication also showed an immune response to the bare 
GNR injections in the mouse eye
36
. After realizing this reaction was taking place, we moved to 
“detoxify” our GNR by replacing the surface CTAB with PEG, which is also considered to be 
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biocompatible
38. While we didn’t assess for immune response to this GNR construct directly, we 
were at least able to inject them intravitreally and image them successfully, without it causing 
gross morphological abnormalities in the eye. 
These intravitreal studies showed us that PEG-coated GNR were viable constructs for in 
vivo imaging experiments, but that they weren’t able to pass into the retina from the vitreous. 
This is not unexpected based on their size. So we moved to intravenous injections of GNR to try 
to study them in the retina. In order to have a good target for our imaging, we used the LCNV 
model to provide localized lesions onto which we could focus our search
42
. Our attempts to 
image GNR natively on OCT were unsuccessful though, since the heterogeneous tissue of the 
retina and of LCNV lesions in particular created too much scattering noise to detect GNR on top 
of it.  
This left us with a problem, since we thought we had a way to deliver GNR to the retina 
and could perform in vivo OCT imaging in a relevant animal model, but we couldn’t see our 
contrast agent.  This led to our establishing collaborations with labs that work on OCT adjuncts, 
which broadly defined are technologies that work in cooperation with OCT systems to provide 
additional data about the imaging targets.  
The first of these we discuss is PT-OCT, and this work was done in collaboration with 
the Skala lab and resulted in two publications
16,56
. Our early experiments established that there is 
already an endogenous absorber in the mouse retina, melanin, which is present in the RPE layer. 
This result was both exciting and frustrating. It presents an imaging target that has potential 
clinical value in AMD or ocular melanoma, for example. Since this imaging requires no contrast 
injections and uses laser powers generally considered permissible in humans, it might be our 
 
 
54 
 
most immediately translatable experimental result. However, the clinical utility of improved 
melanin quantification in the retina has yet to be proven. 
This very strong endogenous contrast agent represented a considerable source of 
background noise for subsequent studies imaging injected GNR in the LCNV model. Much of 
our experimental protocol was designed to minimize this background signal, from the choice of 5 
days post-lasering for our studies to our decision to use blinded hand-selected ROI to assess for 
the presence of our contrast agent, which introduces human error and is quite time consuming. 
The photothermal signal from melanin is currently a barrier to clinical translation of GNR 
imaging using PT-OCT. 
Despite this difficulty, we were able to achieve positive and novel results from our 
studies of PT-OCT imaging of intravenously delivered GNR. We found we could detect both 
untargeted and ICAM2-targeted GNR in LCNV lesions in vivo using PT-OCT. While we 
couldn’t distinguish between these two GNR constructs, there was a trend toward a stronger 
signal from the targeted GNR, which is consistent with a targeting effect. Our most exciting 
result came with the final experiment discussed in Chapter 3. We detected anti-VEGF-induced 
changes in targeted GNR accumulation in LCNV lesions. The combination of LCNV, used to 
model wet AMD, and anti-VEGF injections, used to treat wet AMD, maintained the translational 
relevance of this study. Our ability to detect these clinically relevant physiological changes, 
likely a result of vascular changes caused by anti-VEGF, fulfilled the major goal of our imaging 
studies with OCT and GNR – we were able to move OCT beyond the realm of structural 
imaging.  
An interesting question considered in detail in Chapter 3 is why there is so much apparent 
accumulation of untargeted gold nanorods in LCNV lesions in that study. While the answer is 
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uncertain, it likely involves altered hemodynamics in the lesion as well as damaged or destroyed 
vasculature permitting the extravasation of GNR into surrounding lesion tissue
60
. This is an 
important distinction however, as one might expect untargeted GNR in areas of static blood flow 
to eventually clear from the lesions, while targeted GNR held by antibody-antibody interactions 
might not. This would argue in favor of assessing longer post-injection time points for future 
imaging studies using targeted GNR. A relevant piece of evidence in Chapter 2 is the 
immunohistochemical study of flat mounted retinas treated in the LCNV model and injected with 
targeted vs untargeted nanorods. This protocol was essentially identical to that used in Chapter 3. 
While not quantitative, the results suggest a much higher concentration of targeted GNR relative 
to untargeted GNR in LCNV lesions. While there are issues with the quality of this image, these 
disparate results might suggest that the process of flat mounting itself might remove some of the 
unbound GNR from the lesions, which allows the apparent targeting effect of IHC to be 
consistent with the lack of one of PT-OCT imaging. This does highlight one of the issues with 
the studies we discuss. We were largely unable to perform further optimization of GNR 
constructs, molecular targets, or imaging protocols due to the time required to perform each set 
of experiments.   
In addition to using PT-OCT as an adjunct to image GNR, we also conducted some 
experiments with the Huang lab using SF-OCT to detect GNR, although these experiments were 
conducted in tissue phantoms
30
. SF-OCT was able to detect GNR embedded in tissue phantoms. 
More importantly, it was also able to detect these GNR after they were taken up by RPE cells, 
and the cells themselves were embedded in a tissue phantom. This demonstrates that our GNR 
can interact with the light from OCT systems even from an intracellular position, an example of 
their versatility as contrast agents for use with OCT adjunct technologies.   
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PT-OCT and SF-OCT have their own strengths and weaknesses as OCT adjuncts. PT-
OCT requires an additional laser source, which SF-OCT does not. Additionally, PT-OCT takes 
much longer to complete a scan of a given area than SF-OCT, and this can be as long as 40 
minutes for scanning a complete LCNV lesion. On these counts, SF-OCT has considerably fewer 
barriers to clinical translation. However, in generating its spectral data SF-OCT compromises its 
spatial resolution to a degree, and this spatial resolution is one of the major advantages of OCT 
as a clinical tool. Also, at least in our studies, SF-OCT of GNR has not yet been demonstrated in 
vivo in the eye, while PT-OCT has. Finally, PT-OCT can image a potentially useful endogenous 
contrast source without the need for additional exogenous contrast agents, which improves the 
translatability of this technology. Considering these characteristics, both technologies appear to 
have a path toward clinical translation.  
Regarding translation of the work into a clinical setting, some thought should be given to 
the patient populations that may benefit if retinal physiology and molecular expression are able 
to be visualized by OCT systems, with or without exogenous contrast agents. Regarding the 
leading causes of blindness, there are certain patient populations that are more likely to suffer 
vision loss from the worsening of their disease. The easiest way to identify these patients, and 
therefore select candidates for this novel imaging, would be simply to screen those people with 
pre-existing less severe disease, including diabetic patients (for DR-related changes), patients 
with drusen (for progression to wet AMD), or patients with elevated intraocular pressure (for 
incipient glaucoma). If contrast-enhanced OCT represents a greater time or risk burden for 
patients than standard OCT imaging, this type of pre-screening could maintain the translatability 
of the technology while still allowing it to identify the majority of patients who would benefit 
from earlier disease detection and clinical intervention.  
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